LONDON (Reuters) – AstraZeneca said on Monday its vaccine for the novel coronavirus, developed along with the University of Oxford, could be around 90% effective under one dosing regimen.
“This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency,” Pascal Soriot, Astra’s chief executive, said in a statement.
The British drugmaker’s preliminary trial results mark a fresh breakthrough in the fight against a pandemic that has killed nearly 1.4 million people and roiled the global economy.
(Reporting by Kate Holton in London; Aakash Jagadeesh Babu in Bengaluru; Editing by Shounak Dasgupta/Guy Faulconbridge)
